Pharma & Biotech - Page 8

Clinical digital out-of-home displays installed in medical waiting rooms are gaining recognition as a powerful and largely untapped channel for healthcare advertising. Patients sitting in waiting rooms represent a highly captive audience,

Lundbeck has signed an expanded agreement with Eversana to deploy the company’s AI commercialisation platform more broadly across its entire US commercial organisation. The brain disease specialist initially used Eversana’s AI-driven workflows

Rep. Nathaniel Moran of Texas says America’s political debate around China’s biotech industry is fundamentally missing the point on where the real threat lies. Moran, a Republican member of the House Select

Bausch + Lomb has developed a first-in-class combination eye drop targeting two of the primary underlying causes of dry eye disease simultaneously. The novel treatment combines 5% lifitegrast, the active ingredient in

Vikram Anand, president of compliance services at EVERSANA, has set out a vision for where pharmacovigilance infrastructure is headed next. Anand’s remarks close out a series of conversations with Pharmaceutical Commerce focused

McKesson Corporation is acquiring Precision Medicine Group for $2.25 billion, significantly expanding its drug development and commercialisation capabilities. The healthcare wholesaler, which ranks eighth on the Fortune 500 list, will fold privately

The patient support landscape in 2026 looks fundamentally different from what existed even a decade ago, driven by rapid shifts in specialty medicine. Manufacturers have significantly expanded investment in digital engagement, specialty

Johnson & Johnson has secured a significant regulatory win, with the FDA approving its therapy Imaavy for a second indication targeting a rare and life-threatening blood condition. The approval covers Imaavy, known

Cellares, the automated cell therapy manufacturer that has risen rapidly since its 2019 founding in South San Francisco, is now confronting a significant business setback. Co-founder and CEO Fabian Gerlinghaus revealed over

Eli Lilly (LLY) has released a new campaign spotlighting the decades-long struggles of older obesity patients and its Medicare GLP-1 Bridge program. The campaign, titled “A Life Covered,” is the latest short